Examine how legitimate pharmaceutical export channels are exploited for illicit drug diversion. Suggest regulatory reforms.

Tramadol — a synthetic opioid notified as a psychotropic substance under the NDPS Act, 1985 by notification of April 2018 [2] — shows how India's legitimate pharmaceutical export architecture can itself become the conduit for illicit diversion. The Central Bureau of Narcotics' "Operation Vajra" (July 2026), which seized 12 crore high-strength tablets (~30 metric tons) from a Delhi warehouse, illustrates the scale of the risk [1].

How export channels are exploited

• False destination declaration: the consignment was ostensibly bound for Guinea-Bissau, but was apparently intended for diversion to Libya, using a weakly-regulated West African hub as a transshipment cover [1].
• Cover of lawful documentation: export of psychotropic substances requires a CBN No-Objection Certificate under the NDPS Rules, 1985 [3]; traffickers ride on licensed manufacture and genuine EXIM paperwork rather than evading it.
• High-strength formulations for grey markets: 250 mg tablets, far above ordinary therapeutic use, were produced for destinations with negligible pharmacovigilance [1].
• Fragmented supply chain: sourcing, financing and warehousing were split across Bengaluru, Kochi and Delhi, so no single jurisdiction saw the full chain [1].
• Narco-conflict demand: Tramadol's reputation as a "fighter drug" among armed non-state actors sustains bulk demand in conflict theatres [1].

Regulatory reforms

• End-use verification: make the importing country's import authorisation a mandatory precondition for the CBN NOC, digitally cross-checked with the destination regulator and INCB.
• Track-and-trace: serialisation/barcoding of controlled formulations, with reconciliation of production, export and landing certificates.
• Strength and volume caps: licence high-strength opioid formulations only against documented therapeutic demand, with red flags on sudden volume spikes.
• Data integration: single-window linking of CBN licensing, Customs EDI, DGFT and DRI risk profiling for real-time consignment scoring.
• Accountability and capacity: statutory due-diligence duties on exporters and customs brokers; strengthened CBN field staffing under Section 8(c) enforcement [3].

Operation Vajra confirms that intelligence-led enforcement works, but interception alone cannot substitute for prevention. Shifting from post-shipment detection to verified, traceable, end-use-linked licensing would let India protect its standing as the "pharmacy of the world" while honouring its obligations under the UN drug control conventions.